Edexcel A Level Biology: Molecules, Transport and Health (YBI11)

This guide covers Topic 1 Molecules, Transport and Health, the first of eight topics in Pearson Edexcel International Advanced Subsidiary/Advanced Level Biology (XBI11/YBI11), Issue 2. It is examined as Unit 1, one of three International AS units, alongside Unit 3 (Practical Skills in Biology I). The specification presents this topic as a single sequence of 20 numbered learning outcomes (1.1-1.20) rather than grouping them under named sub-headings, so the coverage below follows that same flat structure while organising it by theme for revision purposes.

Where this fits in YBI11

Topic 1 introduces the biological molecules (carbohydrates and lipids) and the mammalian transport system that recur throughout the rest of the specification, then applies them to a real-world case study — cardiovascular disease — that sets the pattern for how later topics combine molecular detail with data-handling and evaluation skills.

Syllabus coverage

PEARSON EDEXCEL INTERNATIONAL A LEVEL BIOLOGY (YBI11) — TOPIC 1 MOLECULES, TRANSPORT AND HEALTH (learning outcomes 1.1-1.20)

• Water and carbohydrates (1.1-1.4) — water as a solvent and its dipole nature; the structure of monosaccharides, disaccharides and polysaccharides (including glycogen, amylose and amylopectin); Core Practical 1, testing for reducing sugars with Benedict’s reagent and starch with iodine solution; and how condensation and hydrolysis reactions build and break glycosidic bonds
• Lipids and the case for mass transport (1.5-1.6) — triglyceride synthesis by ester bond formation, the difference between saturated and unsaturated lipids, and why animals with a low surface area-to-volume ratio need a heart and circulation to overcome the limits of diffusion
• The heart and blood vessels (1.7-1.9) — how the structures of capillaries, arteries and veins relate to their functions; the cardiac cycle and the structure of the mammalian heart; and the role of haemoglobin in oxygen and carbon dioxide transport, including the Bohr effect and fetal haemoglobin
• Cardiovascular disease (1.10-1.14) — the development of atherosclerosis, the blood clotting process, risk factors for cardiovascular disease (CVD) such as genetics, diet, age, smoking and inactivity, the link between dietary antioxidants and CVD risk, and Core Practical 2, investigating vitamin C content
• Evaluating health risk data (1.15-1.20) — analysing and interpreting mortality and illness data, distinguishing correlation from causation, evaluating study design and sample selection, understanding why perceived and actual risk can differ, interpreting cholesterol and lipoprotein data, and weighing the benefits and risks of CVD treatments such as statins and anticoagulants

Core practicals in detail

Core Practical 1 — testing for reducing sugars and starch. For a reducing sugar (all monosaccharides and some disaccharides, including maltose and lactose, but not sucrose), heat the sample with an excess of Benedict’s reagent in a water bath: a positive result is a colour change from blue through green and orange to a brick-red precipitate of copper(I) oxide, and the test can be made semi-quantitative by comparing colours or timing the change. For starch, adding iodine/potassium iodide solution gives a colour change from orange-brown to blue-black if starch is present.

Core Practical 2 — investigating vitamin C content. This uses DCPIP, a blue dye that is decolourised when reduced by ascorbic acid (vitamin C). A known volume of DCPIP is titrated with the food sample or juice being tested, added dropwise until the blue colour just disappears (the end point). Because DCPIP is fixed and vitamin C is the limiting reagent for decolourising it, the volume needed is inversely proportional to the vitamin C concentration — a more concentrated sample decolourises the same volume of DCPIP in a smaller titre, allowing samples to be ranked or compared against a calibration curve of known vitamin C concentrations.

Haemoglobin, the Bohr effect and fetal haemoglobin

Haemoglobin’s oxygen dissociation curve is sigmoid (S-shaped), not a straight line or simple curve, because binding of the first oxygen molecule changes haemoglobin’s quaternary structure in a way that makes it easier for further oxygen molecules to bind — cooperative binding.

The Bohr effect: a higher concentration of carbon dioxide (as found in actively respiring tissue) shifts the dissociation curve to the right, meaning haemoglobin holds oxygen less tightly at a given oxygen partial pressure and releases more oxygen exactly where it is needed most.

Fetal haemoglobin (HbF) has a different quaternary structure from adult haemoglobin and a higher affinity for oxygen at any given partial pressure — its dissociation curve sits to the left of the adult curve. This allows the fetus to take oxygen from the mother’s blood across the placenta, where the oxygen partial pressure is too low for maternal haemoglobin to release much oxygen but still high enough for fetal haemoglobin to load it.

Evaluating health risk data, statins and anticoagulants

The final learning outcomes (1.15-1.20) test data-handling skills rather than new biological facts: whether a study’s sample size and selection were representative, whether it was properly controlled, and whether perceived risk (how dangerous something feels) matches actual risk (the real statistical likelihood) — people often over-estimate dramatic, rare risks and under-estimate familiar, common ones.

Statins lower blood LDL cholesterol by inhibiting an enzyme in the liver involved in cholesterol synthesis, reducing the cholesterol available to form atheromas — but this benefit has to be weighed against side effects such as muscle pain. Anticoagulants such as warfarin reduce the blood’s ability to clot, lowering the risk of a dangerous thrombus forming — but the same reduced clotting ability raises the risk of serious bleeding if the patient is injured. Both are exam-favourite examples of weighing a treatment’s benefit against its risk, rather than treating either as unconditionally “safe.”

How to approach it

The two core practicals (1.3 and 1.14) are common sources of exam questions on method and evaluation, so know not just how to carry them out but why each reagent and control matters. The final third of the topic (1.15-1.20) is less about biological content and more about data interpretation and evaluation — practise reading unfamiliar mortality and risk data, since this is exactly the kind of source-based question the specification is built to test. Keep the molecular content (1.1-1.5) and the physiological content (1.6-1.9) clearly separate in your notes, then use the cardiovascular disease case study (1.10-1.20) as the thread that ties both back together, since exam questions often ask you to link a molecular or structural fact to its real-world health consequence.

Official syllabus

Pearson Edexcel International Advanced Subsidiary/Advanced Level in Biology specification, Issue 2, February 2021 — qualifications.pearson.com.